T 2137/13 04-10-2017
Download and more information:
Salmeterol superfine formulation
I. The opponent lodged an appeal against the decision of the opposition division of 12 August 2013 to maintain European patent No. 1 553 922 in amended form.
An appeal was lodged also by the patent proprietor but it was subsequently withdrawn.
II. In a communication dated 16 February 2017, the Board informed the parties that the patent in suit had lapsed for all the designated States and invited the appellant-opponent to inform the Board, within two months from notification of the communication, whether it requested a continuation of the appeal proceedings pursuant to Rule 84 EPC.
III. No reply was received from the appellant-opponent within the two month period.
1. Pursuant to Rule 84(1) EPC in conjunction with Rule 100(1), proceedings are not continued after the European patent has lapsed unless there is a request to this effect by the opponent filed within two month as from the notification by the European Patent Office of the lapse.
As in the present case, no such request by the opponent has been received, the proceedings are to be terminated by a decision of the Board.
For these reasons it is decided that:
The appeal proceedings are terminated.